Vitrolife AB is a leading global provider of medical devices and genetic testing services dedicated to the reproductive-health market, specializing in assisted reproduction technologies. The company d... Vitrolife AB is a leading global provider of medical devices and genetic testing services dedicated to the reproductive-health market, specializing in assisted reproduction technologies. The company develops, manufactures, and distributes specialized products such as culture media, sperm processing solutions, and genetic testing services for IVF clinics and their patients worldwide. Its mission focuses on supporting IVF clinics to enhance treatment practices, improve fertility outcomes, and help patients navigate reproductive health challenges through reliable, high-quality solutions that promote successful pregnancies and satisfaction. Operating across three key geographical segments—EMEA, Americas, and APAC—with the majority of revenue from EMEA, Vitrolife AB serves clinics in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. Founded in 1994 and headquartered in Gothenburg, Sweden, the company employs over 1,100 people and maintains rigorous quality control standards that have set industry benchmarks for two decades. Vitrolife AB also offers comprehensive support through its Academy, including webinars, instructional materials, and customized training to optimize lab efficiency and IVF processes, positioning it as a pivotal player in the medical devices sector for fertility treatments.
In 2025, Vitrolife was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Vitrolife has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Vitrolife are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
1.2 CE - Manufacture of electrical and electronic equipment
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Metric
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
1.2 CE - Manufacture of electrical and electronic equipment
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Metric
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
1.2 CE - Manufacture of electrical and electronic equipment
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
7.7 CCM/CCA - Acquisition and ownership of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Limited Data Preview
You are viewing a limited preview of Vitrolife’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories, at both aggregate and activity level, with historical coverage back to 2023.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Verified Sources Behind Vitrolife’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Vitrolife’s data sources below and access millions more through our Disclosure Search.
a. Vitrolife's Annual Report 2025
b. Vitrolife's Annual Report 2024
c. Vitrolife's Annual Report 2023
Insights into Vitrolife's Revenues from Sustainable Activities
In 2025, Vitrolife reported EU Taxonomy-eligible revenues of SEK 0, representing 0% of its total turnover. Of this amount, SEK 0 of Vitrolife's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Vitrolife's Taxonomy-Eligible Turnover Over Time
Total Taxonomy Eligible Turnover
Total Taxonomy Aligned Turnover
Have Vitrolife's revenues become more sustainable over time?
Compared to the previous year (2024), Vitrolife's taxonomy-aligned revenues decreased by 100%, suggesting that Vitrolife may have deprioritized sustainable activities, shifted focus away from green offerings, or reduced transparency in its EU Taxonomy reporting.a, b
Insights into Vitrolife's CAPEX from Sustainable Activities
In 2025, Vitrolife reported EU Taxonomy-eligible CAPEX of SEK 37.70 million,representing 13% of its total CAPEX. Of this amount, SEK 7.80 million of Vitrolife's CAPEX was classified as EU Taxonomy-aligned, indicating that 3% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Vitrolife's Taxonomy-Eligible Capex Over Time
Total Taxonomy Eligible Capex
Total Taxonomy Aligned Capex
Have Vitrolife's increased its investment in sustainable activities over time?
Compared to the previous year (2024), Vitrolife's taxonomy-aligned CAPEX decreased by 72.73%,suggesting that Vitrolife may have scaled back investments in sustainable projects, reprioritized its capital deployment, or reduced transparency in its taxonomy-aligned disclosures.a, b
How much of Vitrolife's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2025, Vitrolife reported that SEK 37.70 million of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 13% of the company's total CAPEX. Of this amount, SEK 7.80 million (3% of total CAPEX) was classified as Taxonomy-aligned. This means that 10% of Vitrolife's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Vitrolife's eligible CAPEX is aligned with the EU Taxonomy?
In 2025, Vitrolife reported that SEK 7.80 million of its CAPEX was aligned under the EU Taxonomy, representing 3% of its total capital investment.a
This low alignment reflects that Vitrolife is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
Vitrolife's Eligibility & Alignment Overview
Vitrolife's Contribution to Environmental Objectives
Total Taxonomy Aligned Capex
How is Vitrolife's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2025, Vitrolife reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 3%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much Vitrolife is investing in climate-related solutions?
In 2025, Vitrolife allocated SEK 8.70 million of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 3% of the company's total capital expenditure,indicating that Vitrolifehas only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.a
Insights into Vitrolife's OPEX from Sustainable Activities
In 2025, Vitrolife reported EU Taxonomy-eligible OPEX of SEK 0,representing 0% of its total operating expenses (OPEX). Of this amount, SEK 0 of Vitrolife's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Vitrolife's Taxonomy-Eligible Opex Over Time
Total Taxonomy Eligible Opex
Total Taxonomy Aligned Opex
Have Vitrolife's increased its spending in sustainable activities over time?
Compared to the previous year (2024), Vitrolife's taxonomy-aligned OPEX decreased by 100%, suggesting that Vitrolife may have reduced spending on environmentally sustainable activities, adjusted its operational priorities, or decreased the scope of its taxonomy-related disclosures.a, b
Want Full Access to Vitrolife's EU Taxonomy Dataset?
b
c
b
b
b
b
a
b